DOCSLIB.ORG

Sample Identification and Tracking in Biobanks

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sample Identification and Tracking in Biobanks Sample Identification and Tracking in Biobanks A thesis submitted to University of Dublin, Trinity College for the degree of Doctor of Philosophy Atieh Zarabzadeh Department of Computer Science Trinity College Dublin October 2009 Declaration I, the undersigned, declare that this work has not been previously submitted as an exercise for a degree at this or any other University, and that, unless otherwise stated, it is entirely my own work. ______________________ Atieh Zarabzadeh October 2009 i Permission to lend or copy I, the undersigned, agree that the Trinity College Library may lend or copy this thesis upon request. ______________________ Atieh Zarabzadeh October 2009 ii Dedication To my parents... iii Acknowledgment I would like to express my appreciation to all those without whose help I would not have been able to complete this thesis. First and foremost I offer my sincerest gratitude to my supervisor, Prof. Jane Grimson for her invaluable support, supervision and encouragement. I would like to express my profound thanks to Prof. William Watson, University College Dublin, for his patient support and valuable suggestions that enabled me observe the world from a different window. Completing this thesis without Jane and Bill‟s advice would not have been possible. I am grateful to the Irish Prostate Cancer Research Consortium members for their support in the first year when I was learning about the biobanks, and for their kind cooperation during the evaluation phase. I am especially grateful to Ms. Marie Burke, Dr. Linda Sullivan, Dr. Ruth Foley and Dr. Antoinette Perry. I really appreciate the kindness of Dr. Darach Golden and Dr. Geoff Bradley from the Trinity Centre for High Performance Computing during all these years and especially during the last few months for setting up a test server and allowing me to work in their office. I also wish to express my thanks to the Irish Research Council for Science, Engineering and Technology and Hewlett-Packard for providing funding for this project, without which life would have been difficult. In my daily work I have been blessed with a friendly and cheerful group in the Center for Health Informatics (CHI) laboratory. Their support and encouragement made long working hours tolerable. I wish to express my appreciation to former and current staff and students in the School of Computer Science and Statistics. I am thankful to all my friends for their supports, encouragements and advice. I am deeply indebted to Farzad Hayati for his support, encouragement and help in the implementation phase of the project and beyond. I am grateful to Karen Tierney and Sinead Kelleher for editing and proofreading my thesis and to Ronan McDonnell and iv Dr. Bridget Kane for their advice throughout all these years. I am also indebted to Maureen D‟Arcy for her kindness during the times I was under pressure. I would also like to express my thanks to Dr. Mohammad Jamshidi. I would like to express my love and gratitude to my beloved family; for their understanding and endless love not only throughout the duration of my studies but also throughout all my entire life. My parents, Nasrin and Mohsen; and my sister, Talieh are the best I could ever have. v Abstract Biobanks or bio-repositories facilitate the storage and maintenance of biological samples and data to support discovery of biomarkers, therapeutic targets, and the underlying causes of diseases. Such discoveries require high quality samples that are supported by their associated data. While samples and their data are of crucial importance, they are expensive to collect and maintain. Samples and data are subject to various procedures from data collection from the sample donors, to clinical laboratory analyses, to processing in the research laboratory (omic procedures) and ultimately to knowledge discovery. Samples are transferred between different locations and moved in and out of freezers at several different points in this workflow, increasing the potential of error in sample identification and incorrect linkage with the corresponding data. Implementing a robust and reliable Sample Identification and Tracking System (SITS) which can track samples through all the various phases in different locations and at the same time protecting the confidentiality of the sample donors represents a major challenge. In this thesis a novel method has been developed based on Radio Frequency Identification (RFID) technology to support reliable tracking of samples from collection to knowledge discovery. In this system RFID tags are attached to the tubes containing the samples and send and receive data to and from the users through a web based interface. These RFID tags are passive, allowing longer life span than active RFID tags, rewriteable and survive extreme temperatures. They have small physical size and store dynamic data to support biobank activities. In addition to sample tracking, this system improves quality control of samples by recording details of collection, procedure and storage data such as Standard Operating Procedures (SOPs) under which the sample has been collected and processed. The SITS prototype has been evaluated by the Irish Prostate Cancer Research Consortium (PCRC) biobank, a federated biobank for prostate cancer. vi Publications Related to This PhD 1. Zarabzadeh, A., Hayati, F., Watson, R. W. G., Bradley, G., Grimson, J. (2009) An Overview of Sample Identification and Tracking System for Biobanks: Abstract for the 14th Annual Conference and Scientific Symposium of the Healthcare Informatics Society of Ireland (HISI). Dublin, Ireland. 2. Zarabzadeh, A., Hayati, F., Watson, R. W. G., Bradley, G., Grimson, J. (2009) A Sample Identification and Tracking System for Biobanks: Proceedings of the 22nd IEEE International Symposium on Computer-Based Medical Systems (CBMS 2009). New Mexico, USA. 3. Zarabzadeh, A., Watson, R. W. G., Bradley, G., Grimson, J. (2008) Participants Confidentiality in Prostate Cancer Research Consortium Bio-repository: Abstract for the 13th Annual Conference and Scientific Symposium of the Healthcare Informatics Society of Ireland (HISI). Dublin, Ireland. 4. Zarabzadeh, A., R. W. G. Watson, et al. (2009). Ensuring participant privacy in networked biobanks. Principles and Practice in Biobank Governance. J. Kaye and M. Stranger, Ashgate. 5. Zarabzadeh, A., Watson, R. W. G., Bradley, G., Grimson, J. (2008) Ensuring Participant Confidentiality in Bio-repositories: Abstract for Conference on Governing Biobanks – What are the challenges? Oxford, UK. 6. Zarabzadeh, A., Watson, R. W. G., Grimson, J. (2008) The use of Radio Frequency Identification to Track Samples in Bio-repositories: Proceedings of the IEEE 1st International Conference on Information Technology (IT2008). Gdansk, Poland. pp.351-354. 7. Zarabzadeh, A., Watson, R. W. G., Bradley, G., Grimson, J. (2007) Sample Tracking and Identification in Biobanks: Abstract for the 12th Annual Conference and Scientific Symposium of the Healthcare Informatics Society of Ireland (HISI). Dublin, Ireland. vii Table of Contents List of Figures .................................................................................................................... i List of Tables ................................................................................................................... vii Abbreviations ................................................................................................................... ix Chapter 1. Introduction .................................................................................................. 1 1.1 Motivation ........................................................................................................... 1 1.2 Research Question ............................................................................................... 6 1.3 Research Goals and Objectives ........................................................................... 6 1.4 Research Contribution ......................................................................................... 8 1.5 Thesis Overview .................................................................................................. 9 Chapter 2. Sample Identification and Tracking Systems ............................................. 11 2.1 Introduction ....................................................................................................... 11 2.2 Biobanking ........................................................................................................ 12 2.3 Sample and Data Journey .................................................................................. 20 2.4 Biobank Information Management Systems ..................................................... 25 2.5 The Irish Prostate Cancer Research Consortium (PCRC) Biobank .................. 29 2.6 Currently Available SITS................................................................................... 40 2.7 SITS Requirements ............................................................................................ 48 2.8 Conclusion ......................................................................................................... 50 Chapter 3. Confidentiality............................................................................................ 53 3.1 Introduction ....................................................................................................... 53 viii 3.2 Confidentiality in Biobanks ............................................................................... 54 3.3 Best
Load more

Recommended publications
  • Guidelines for Securing Radio Frequency Identification (RFID) Systems
    Special Publication 800-98 Guidelines for Securing Radio Frequency Identification (RFID) Systems Recommendations of the National Institute of Standards and Technology Tom Karygiannis Bernard Eydt Greg Barber Lynn Bunn Ted Phillips NIST Special Publication 800-98 Guidelines for Securing Radio Frequency Identification (RFID) Systems Recommendations of the National Institute of Standards and Technology Tom Karygiannis Bernard Eydt Greg Barber Lynn Bunn Ted Phillips C O M P U T E R S E C U R I T Y Computer Security Division Information Technology Laboratory National Institute of Standards and Technology Gaithersburg, MD 20899-8930 April 2007 US Department of Commerce Carlos M. Gutierrez, Secretary Technology Administration Robert C. Cresanti, Under Secretary of Commerce for Technology National Institute of Standards and Technology William Jeffrey, Director GUIDELINES FOR SECURING RFID SYSTEMS Reports on Computer Systems Technology The Information Technology Laboratory (ITL) at the National Institute of Standards and Technology (NIST) promotes the US economy and public welfare by providing technical leadership for the nation’s measurement and standards infrastructure. ITL develops tests, test methods, reference data, proof of concept implementations, and technical analysis to advance the development and productive use of information technology. ITL’s responsibilities include the development of technical, physical, administrative, and management standards and guidelines for the cost-effective security and privacy of sensitive unclassified information in Federal computer systems. Special Publication 800-series documents report on ITL’s research, guidelines, and outreach efforts in computer security and its collaborative activities with industry, government, and academic organizations. National Institute of Standards and Technology Special Publication 800-98 Natl.
    [Show full text]
  • The Development of Large-Scale De-Identified Biomedical Databases in the Age of Genomics—Principles and Challenges Fida K
    Dankar et al. Human Genomics (2018) 12:19 https://doi.org/10.1186/s40246-018-0147-5 REVIEW Open Access The development of large-scale de-identified biomedical databases in the age of genomics—principles and challenges Fida K. Dankar1* , Andrey Ptitsyn2 and Samar K. Dankar3 Abstract Contemporary biomedical databases include a wide range of information types from various observational and instrumental sources. Among the most important features that unite biomedical databases across the field are high volume of information and high potential to cause damage through data corruption, loss of performance, and loss of patient privacy. Thus, issues of data governance and privacy protection are essential for the construction of data depositories for biomedical research and healthcare. In this paper, we discuss various challenges of data governance in the context of population genome projects. The various challenges along with best practices and current research efforts are discussed through the steps of data collection, storage, sharing, analysis, and knowledge dissemination. Keywords: Biomedical database, Data privacy, Data governance, Whole genome sequencing Background first, now increasingly shifting to whole exome and whole Overview genome sequencing [2, 3]). The project started by Decode Databases are both the result and the instrument of has generated one of the best resources for discovery in research. From the earliest times, assembling collections biomedical sciences and inspired development of multiple of samples and stories was essential for any research pro- populational and national genomics projects, also feeding ject. The results of research feeding back into the libraries into integrated databases. Genomics England [4], Human and collections create a positive feedback in the accumula- Longevity [5], All of US (formerly known as Precision tion of knowledge limited only by the technological plat- Medicine Initiative) [6], China’s Precision Medicine Initia- form for storage and retrieval of information.
    [Show full text]
  • 'Iceland Inc.'?: on the Ethics of Commercial Population Genomics
    University of Pennsylvania ScholarlyCommons Center for Bioethics Papers Center for Bioethics March 2004 'Iceland Inc.'?: On the ethics of commercial population genomics Jon F. Merz University of Pennsylvania, [email protected] Glenn E. McGee University of Pennsylvania Pamela Sankar University of Pennsylvania Follow this and additional works at: https://repository.upenn.edu/bioethics_papers Recommended Citation Merz, J. F., McGee, G. E., & Sankar, P. (2004). 'Iceland Inc.'?: On the ethics of commercial population genomics. Retrieved from https://repository.upenn.edu/bioethics_papers/52 Postprint version. Published in Social Science and Medicine, Volume 58, Issue 6, March 2004, pages 1201-1209. Publisher URL: http://dx.doi.org/10.1016/S0277-9536(03)00256-9 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/bioethics_papers/52 For more information, please contact [email protected]. 'Iceland Inc.'?: On the ethics of commercial population genomics Abstract A detailed analysis of the Icelandic commercial population-wide genomics database project of deCODE Genetics was performed for the purpose of providing ethics insights into public/private efforts to develop genetic databases. This analysis examines the moral differences between the general case of governmental collection of medical data for public health purposes and the centralized collection planned in Iceland. Both the process of developing the database and its design vary in significant ways from typical government data collection and analysis activities. Because of these differences, the database may serve the interests of deCODE more than it serves the interests of the public, undermining the claim that presumed consent for this data collection and its proprietary use is ethical.
    [Show full text]
  • Biobanks for Europe
    KI-NA-25-302-EN-C This expert group report on the ethical and regulatory challenges of international biobank research has been authored by an interdisciplinary group with experts from science, law, governance and ethics. Biobanks for Biobank research is rapidly evolving, and in close interaction with developments in informatics and genomics. The size and breath of the collections of biological samples and associated data that can be Europe assembled has increased exponentially. This opens up a vast range of new options for research and diagnosis, but at the same time also holds an important challenge for the governance of these activities. In this report, the expert group makes speci c recommendations for good A Challenge for Governance governance of Biobanks Research and Innovation policy Research and Innovation ed205134cover_BAT.indd 1-3 11/06/12 09:14 How to obtain EU publications Free publications: • via EU Bookshop (http://bookshop.europa.eu); • at the European Union’s representations or delegations. You can obtain their contact details on the Internet (http://ec.europa.eu) or by sending a fax to +352 2929-42758. Priced publications: • via EU Bookshop (http://bookshop.europa.eu). Priced subscriptions (e.g. annual series of the O cial Journal of the European Union and reports of cases before the Court of Justice of the European Union): • via one of the sales agents of the Publications O ce of the European Union (http://publications.europa.eu/others/agents/index_en.htm). EUROPEAN COMMISSION Directorate-General for Research and Innovation Directorate B — European Research Area Unit B6 — Ethics and gender Contact: Lino PAULA European Commission B-1049 Brussels E-mail: [email protected] ed205134cover_BAT.indd 4-6 11/06/12 09:14 EUROPEAN COMMISSION Biobanks for Europe A challenge for governance Report of the Expert Group on Dealing with Ethical and Regulatory Challenges of International Biobank Research Chair: Herbert Gottweis Rapporteur: Jane Kaye Members: Fabrizia Bignami, Emmanuelle Rial-Sebbag, Roberto Lattanzi, Milan Macek Jr.
    [Show full text]
  • Tesi Definitiva
    UNIVERSITA’ DEGLI STUDI DI TORINO FACOLTA’ DI ECONOMIA CORSO DI LAUREA IN ECONOMIA E DIREZIONE DELLE IMPRESE RELAZIONE DI LAUREA INNOVATIVI DISPOSITIVI TECNOLOGICI PER UNA MAGGIORE INFORMAZIONE DEL CONSUMATORE NEL SETTORE AGROALIMENTARE: UNO STUDIO AL SALONE DEL GUSTO 2010 Relatore: Prof. Giovanni Peira Correlatori: Prof. Luigi Bollani Dott. Sergio Arnoldi Candidato: Andrea Gino Sferrazza ANNO ACCADEMICO 2010/2011 Ringraziamenti Ringrazio per la stesura di questo lavoro: - il Prof. Giovanni Peira del Dipartimento di Scienze Merceologiche, per avermi seguito e aiutato durante questo lavoro, fornendomi parte del materiale di studio, indicandomi alcune persone cruciali per la buona riuscita della stesura e per la sua completa disponibilità durante quesi mesi di ricerche; - il Prof. Luigi Bollani, del Dipartimento di Statistica e Matematica applicata “Diego de Castro”, per il suo fondamentale contributo nell’impostazione e nell’elaborazione del questionario, proposto durante il Salone del Gusto 2010; - il Dott. Sergio Arnoldi, coordinatore dell’Area Promozione Agroalimentare della Camera di commercio di Torino, il quale ha messo a disposizione tempo e risorse preziose per questo progetto di ricerca, sempre con molta professionalità e competenza; - il Dott. Alessandro Bonadonna del Dipartimento di Scienze Merceologiche, per avermi fornito preziosi spunti per la trattazione; - tutti coloro che mi hanno supportato nella stesura ed elaborazione del questionario, rendendo possibile il raggiungimento degli obiettivi prefissati nei tempi prestabiliti. Ringraziamenti particolari Il primo ringraziamento va a mia madre, l’unica vera persona che mi ha accompagnato in ogni momento durante il mio percorso di studio. Senza di lei, non avrei potuto raggiungere questo importante traguardo. Questo risultato lo divido con te.
    [Show full text]
  • Incentivizing the Utilization of Pharmacogenomics in Drug Development Valerie Gutmann Koch
    Journal of Health Care Law and Policy Volume 15 | Issue 2 Article 3 Incentivizing the Utilization of Pharmacogenomics in Drug Development Valerie Gutmann Koch Follow this and additional works at: http://digitalcommons.law.umaryland.edu/jhclp Part of the Chemicals and Drugs Commons, and the Health Law Commons Recommended Citation Valerie G. Koch, Incentivizing the Utilization of Pharmacogenomics in Drug Development, 15 J. Health Care L. & Pol'y 263 (2012). Available at: http://digitalcommons.law.umaryland.edu/jhclp/vol15/iss2/3 This Article is brought to you for free and open access by DigitalCommons@UM Carey Law. It has been accepted for inclusion in Journal of Health Care Law and Policy by an authorized administrator of DigitalCommons@UM Carey Law. For more information, please contact [email protected]. INCENTIVIZING THE UTILIZATION OF PHARMACOGENOMICS IN DRUG DEVELOPMENT VALERIE GUTMANN KOCH* I. INTRODUCTION The last decades have witnessed remarkable advancements in the fields of genetics and genomics, highlighted by the successful completion of the map of the human genome in 2003.' With this achievement came scientific possibilities that, only a few decades earlier, seemed more science fiction than reality. Of these developments, pharmacogenomics is hailed by many as a panacea for problems associated with pharmaceutical drug use and development.2 The Human Genome Project (HGP) and associated research have demonstrated that all human beings share 99.9 percent of their DNA. 3 Pharmacogenomics focuses on the 0.1 percent differences between individuals and promises to allow physicians to tailor a patient's prescription according to his or her genetic profile, reducing painful and sometimes deadly side effects, ensuring appropriate dosage decisions, and targeting specific disease pathways.4 Copyright © 2012 by Valerie Gutmann Koch.
    [Show full text]
  • LG4690 Healthcare Life Scien
    Healthcare and Life Sciences Group MERGERS & ACQUISITIONS hrough decades of experience in many of the transactions that have Tdefi ned the healthcare and life sciences industry, Sullivan & Cromwell offers clients comprehensive legal expertise paired with a practical understanding of commercial realities. With a multidisciplinary and integrated global practice, we provide our healthcare and life sciences clients with leading edge transactional advice, expertise on intellectual property intensive matters and deep litigation experience that is critical to the successful execution and consummation of deals and the resolution of disputes. As the following pages demonstrate, Sullivan & Cromwell’s Healthcare and Life Sciences Group has had the privilege of working on a number of transactions that have transformed the healthcare industry. We are grateful that our clients have trusted us with many of the industry’s most signifi cant matters. We look forward to working with existing and new clients and bringing to bear our industry expertise and experience in what promises to be another exciting year in dealmaking as companies continue to position themselves strategically in an ever-evolving industry. 1 Timeline of S&C’s Headline Healthcare and Google Life Sciences S&C client Google Life Life Sciences Transactions Sciences (U.S.) announces Royal Philips its formation as the fi rst of S&C client Royal Philips Baker Bros. Advisors the Alphabet companies, (Netherlands) completes S&C client Baker Bros. Advisors (U.S.) announces their funds role Bayer Verily
    [Show full text]
  • Healthcare Conference
    25th Annual HEALTHCARE CONFERENCE Healthcare Westin St. Francis San Francisco January 8–11, 2007 JPMorgan cordially invites you to attend the 25th Annual Healthcare Conference, January 8 –11, 2007, at the Westin St. Francis in San Francisco. JPMorgan’s premier conference on the healthcare industry will feature more than 260 public and private companies over four days of simultaneous sessions. In addition, the conference will host topical panel discussions featuring leading industry experts. Preliminary List of Invited Presenting Companies Actelion Ltd Baxter International Inc. Cooper Companies Aetna Incorporated BD (Becton, Dickinson) Coventry Affymetrix, Inc. Beckman Coulter, Inc. Dade Behring Holdings, Inc. Alcon, Inc. Bioenvision, Inc. DaVita Inc. Align Technology, Inc. Biogen Idec deCODE genetics, Inc. Allscripts Healthcare Solutions Inc. Biomet, Inc. Digene Altana Boston Scientific Corporation Digirad Corporation — US American Medical Systems Holdings Inc. Bristol-Myers Squibb Company Diversa Corporation Amerigroup Corp. Cambrex Corporation DJO Incorporated AmerisourceBergen Cardinal Health, Inc. Dyax Corp. Amgen, Inc. Caremark Rx, Inc. Eclipsys Corporation AMN Healthcare Services, Inc. Celgene Corporation Edwards Lifesciences Corporation AmSurg Corporation Cell Genesys Elan Corporation, plc Anadys Pharmaceuticals CENTENE Corporation Eli Lilly and Company Applied Biosystems Group Cephalon, Inc. Emdeon Ariad Pharmaceuticals, Inc. Cerner Corporation Emergency Medical Services Corporation AstraZeneca Group plc Charles River Laboratories,
    [Show full text]
  • 3 Security Threats for RFID Systems
    FIDIS Future of Identity in the Information Society Title: “D3.7 A Structured Collection on Information and Literature on Technological and Usability Aspects of Radio Frequency Identification (RFID)” Author: WP3 Editors: Martin Meints (ICPP) Reviewers: Jozef Vyskoc (VaF) Sandra Steinbrecher (TUD) Identifier: D3.7 Type: [Template] Version: 1.0 Date: Monday, 04 June 2007 Status: [Deliverable] Class: [Public] File: fidis-wp3-del3.7.literature_RFID.doc Summary In this deliverable the physical properties of RFID, types of RFID systems basing on the physical properties and operational aspects of RFID systems are introduced and described. An overview on currently know security threats for RFID systems, countermeasures and related cost aspects is given. This is followed by a brief overview on current areas of application for RFID. To put a light on status quo and trends of development in the private sector in the context of RFID, the results of a study carried out in 2004 and 2005 in Germany are summarised. This is followed by an overview on relevant standards in the context of RFID. This deliverable also includes a bibliography containing relevant literature in the context of RFID. This is published in the bibliographic system at http://www.fidis.net/interactive/rfid-bibliography/ Copyright © 2004-07 by the FIDIS consortium - EC Contract No. 507512 The FIDIS NoE receives research funding from the Community’s Sixth Framework Program FIDIS D3.7 Future of Identity in the Information Society (No. 507512) Copyright Notice: This document may not be copied, reproduced, or modified in whole or in part for any purpose without written permission from the FIDIS Consortium.
    [Show full text]
  • Personalised Medicine in the Nordic Countries
    PERSONALISED MEDICINE IN THE NORDIC COUNTRIES NOS-M REPORT WITH CONCLUSIONS AND RECOMMENDATIONS FOR JOINT ACTIONS IN PERSONALISED MEDICINE IN THE NORDIC COUNTRIES CONTENTS EXECUTIVE SUMMARY 3 WORKSHOP REPORT – NORDIC COMMON STRENGTHS AND FUTURE 6 POTENTIAL IN THE FIELD OF PERSONALISED MEDICINE. APPENDIX 1 MAPPING REPORT – PERSONALISED MEDICINE 14 IN THE NORDIC COUNTRIES. APPENDIX 2 Introduction 16 What is Personalised Medicine? Why is Personalised Medicine a Strategic Priority for the Nordic Countries? Aims and Scope of this Report Current Trends in Personalised Medicine 18 Strategic Initiatives and Funding Strategies Challenges for Nordic Collaboration Knowledge Gaps State of Personalised Medicine in the Nordic Region 22 Common Nordic Initiatives Common Nordic Calls Nordic Conferences on Personalised Medicine Current Strategies and Initiatives in the Nordic Countries 30 Denmark Estonia Finland Iceland Norway Sweden State of Personalised Medicine in Europe 52 Common European Initiatives Global State of Personalised Medicine 56 Genomics Initiatives Personalised Medicine Strategic Initiatives 2 EXECUTIVE SUMMARY Background The Joint Committee of the Nordic Medical Research Councils (NOS-M) is a cooperative body for the medical research councils of the Nordic countries. The organisation aims to coordinate and promote medical research in the Nordic countries, to monitor its progress, and to facilitate information exchange among the countries. NOS-M has published two white papers (2011 and 2014) with recommendations on actions needed for the Nordic region to maintain a competitive global position in medical research by responding to scientific, health care and economic challenges. In the NOS-M white paper from 2014, personalised medicine was identified as one of the areas where cooperation can enable the Nordic countries to become world leaders.
    [Show full text]
  • Biobanks and the Public. Governing Biomedical Research Resources in Europe
    Biobanks and the Public. Governing Biomedical Research Resources in Europe. A Report from the BBMRI Project BBMRI_Master_Galley.indd 3 2013/06/05 19:35 BBMRI_Master_Galley.indd 4 2013/06/05 19:35 Biobanking and Biomolecular Resources Research Infrastructure (BBMRI) BIOBANKS AND THE PUBLIC Governing Biomedical Research Resources in Europe BBMRI Biobanking and Biomolecular Resources Research Infrastructure BBMRI_Master_Galley.indd 5 2013/06/05 19:35 BBMRI_Master_Galley.indd 6 2013/06/05 19:35 THIS REPORT PROVIDES A SUMMARY OF the research undertaken by the Working Group on Ethical, Legal, and Social Issues (ELSI) of the Biobanking and Biomolecular Resources Research Infrastructure (BBMRI) project, a major effort funded by the European Commission and aimed at coordinating biomedical resource collections in Europe. The explicit goal of the ELSI sub-project was to provide guid- ance and advice on the governance of biobanks and biomolecu- lar resource collections. The material presented in the following is based on empirical research—in the form of numerous “focus group” interviews—as well as a series of meetings and discus- sions of the experts participating in the BBMRI/ELSI effort. As such, what follows represents perhaps the most comprehensive collection of materials related to the political and social gover- nance of biobanks and biomolecular resource collections in Eu- rope today. This summary guide was written for a very broad audience, including government officials, medical researchers or biobank practitioners, corporate managers, journalists, represen- tatives of NGOs, and members of the informed public. In itself, this report reflects the main conclusion of our research: In order to be successful in the long term, biobanks must engage with the public.
    [Show full text]
  • Biobanks in Europe: Prospects for Harmonisation and Networking
    Biobanks in Europe: Prospects for Harmonisation and Networking Eleni Zika, Daniele Paci, Tobias Schulte in den Bäumen, Anette Braun, Sylvie RijKers- Defrasne, Mylène Deschênes, Isabel Fortier, Jens Laage-Hellman, Christian A. Scerri, Dolores Ibarreta EUR 24361 EN - 2010 The mission of the JRC-IPTS is to provide customer-driven support to the EU policy-making process by developing science-based responses to policy challenges that have both a socio- economic as well as a scientific/technological dimension. European Commission Joint Research Centre Institute for Prospective Technological Studies Contact information Address: Edificio Expo. c/ Inca Garcilaso, 3. E-41092 Seville (Spain) E-mail: [email protected] Tel.: +34 954488318 Fax: +34 954488300 http://ipts.jrc.ec.europa.eu http://www.jrc.ec.europa.eu Legal Notice Neither the European Commission nor any person acting on behalf of the Commission is responsible for the use which might be made of this publication. Europe Direct is a service to help you find answers to your questions about the European Union Freephone number (*): 00 800 6 7 8 9 10 11 (*) Certain mobile telephone operators do not allow access to 00 800 numbers or these calls may be billed. A great deal of additional information on the European Union is available on the Internet. It can be accessed through the Europa server http://europa.eu/ JRC57831 EUR 24361 EN ISBN 978-92-79-15783-7 ISSN 1018-5593 DOI 10.2791/41701 Luxembourg: Publications Office of the European Union © European Union, 2010 Reproduction is authorised provided the source is acknowledged Printed in Spain Reviewers Jane Kaye (University of Oxford, UK) Thorkild I.A.
    [Show full text]